Linp.Ns
LINP.NS is a pharmaceutical company that develops, manufactures, and markets a range of prescription drugs and therapies, primarily generating revenue through the sale of its pharmaceutical products to hospitals, pharmacies, and healthcare providers.
Business. LINP.NS is a pharmaceutical company that develops, manufactures, and markets a range of prescription drugs and therapies, primarily generating revenue through the sale of its pharmaceutical products to hospitals, pharmacies, and healthcare providers.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
LINP.NS is a pharmaceutical company that develops, manufactures, and markets a range of prescription drugs and therapies, primarily generating revenue through the sale of its pharmaceutical products to hospitals, pharmacies, and healthcare providers.
LINP.NS maintains a strong liquidity position, with a current ratio of 4.71, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. The company also has no long-term debt, which further supports its liquidity profile and reduces financial risk. Free cash flow stands at INR 723.96 million, reflecting the company's ability to generate cash after capital expenditures.
In terms of profitability, LINP.NS reports a return on equity (ROE) of 12.26% and a return on assets (ROA) of 10.33%, both of which are strong indicators of efficient capital use and asset management. These figures suggest that the company is generating solid returns for its shareholders and effectively utilizing its asset base to drive earnings. Gross profit of INR 3.19 billion and operating income of INR 886.30 million further support the company's profitability.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the data does not specify revenue by region, but the company is likely focused on the Indian market given the currency and ticker listing. This concentration may expose the company to regional economic and regulatory risks.
LINP.NS has demonstrated consistent revenue growth, with a total revenue of INR 6.23 billion in the latest reporting period. While no prior period data is provided to calculate a year-over-year growth rate, the company's strong operating cash flow of INR 930.16 million and free cash flow of INR 723.96 million suggest a stable and growing business. The company's capital expenditures of INR 192.44 million indicate ongoing investment in its operations.
The risk assessment for LINP.NS indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.0 suggests a conservative capital structure with no long-term debt obligations. Additionally, the absence of dilution risk and the low probability of near-term equity issuance support the company's financial stability.
Recent events and disclosures for LINP.NS do not include any material changes or significant risks that would impact the company's operations or financial position. Analysts have assigned a mean recommendation of 2.00, indicating a generally positive outlook, with one "buy" rating and no "sell" or "strong sell" ratings. The company's last actual EPS was INR 41.11, and its revenue of INR 6.23 billion aligns with its strong financial performance.
- LINP.NS has a strong liquidity position with a current ratio of 4.71 and no long-term debt.
- The company generates solid returns, with a ROE of 12.26% and ROA of 10.33%.
- LINP.NS has a conservative capital structure and low liquidity and dilution risk.
- The company's revenue is concentrated in a single segment and likely focused on the Indian market.
- Analysts have a generally positive outlook, with one "buy" rating and no "sell" ratings.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- LINP.NS Market data — financials · 2026-05-28
- Lincoln Pharmaceuticals Ltd Market data — analyst estimates · 2026-05-28